Modeling and simulation is poised to transform drug development across the entire lifecycle from discovery to commercialization. For the biopharmaceutical industry, this transformation will enable knowledge-based decision making and foster new collaborative ways of working that will translate into more high-value treatments and increased development efficiencies. In the healthcare arena where value for money is paramount, modeling and simulation will inform future healthcare planning and practice.

This three-part series explores the potential of modeling and simulation practice throughout the drug development process. Part 1 discusses the concept of lifecycle modeling and simulation and its current applications in early drug development. Part 2 will consider expanding applications in Phases I-III, including portfolio management. Part 3 will examine modeling and simulation practice and potential in the post-approval arena, including applications aimed at improving healthcare planning and delivery.